TY - JOUR
T1 - Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations
AU - Ricci, Francesca
AU - Bizzaro, Francesca
AU - Cesca, Marta
AU - Guffanti, Federica
AU - Ganzinelli, Monica
AU - Decio, Alessra
AU - Ghilardi, Carmen
AU - Perego, Patrizia
AU - Fruscio, Robert
AU - Buda, Alessro
AU - Milani, Rodolfo
AU - Ostano, Paola
AU - Chiorino, Giovanna
AU - Bani, Maria Rosa
AU - Damia, Giovanna
AU - Giavazzi, Raffaella
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. On the basis of its histopathology and molecular-genomic changes, ovarian cancer has been divided into subtypes, each with distinct biology and outcome. The aim of this study was to develop a panel of patient-derived EOC xenografts that recapitulate the molecular and biologic heterogeneity of human ovarian cancer. Thirty-four EOC xenografts were successfully established, either subcutaneously or intraperitoneally, in nude mice. The xenografts were histologically similar to the corresponding patient tumor and comprised all the major ovarian cancer subtypes. After orthotopic transplantation in the bursa of the mouse ovary, they disseminate into the organs of the peritoneal cavity and produce ascites, typical of ovarian cancer. Gene expression analysis and mutation status indicated a high degree of similarity with the original patient and discriminate different subsets of xenografts. They were very responsive, responsive, and resistant to cisplatin, resembling the clinical situation in ovarian cancer. This panel of patient-derived EOC xenografts that recapitulate the recently type I and type II classi fication serves to study the biology of ovarian cancer, identify tumor-speci fi c molecular markers, and develop novel treatment modalities..
AB - Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. On the basis of its histopathology and molecular-genomic changes, ovarian cancer has been divided into subtypes, each with distinct biology and outcome. The aim of this study was to develop a panel of patient-derived EOC xenografts that recapitulate the molecular and biologic heterogeneity of human ovarian cancer. Thirty-four EOC xenografts were successfully established, either subcutaneously or intraperitoneally, in nude mice. The xenografts were histologically similar to the corresponding patient tumor and comprised all the major ovarian cancer subtypes. After orthotopic transplantation in the bursa of the mouse ovary, they disseminate into the organs of the peritoneal cavity and produce ascites, typical of ovarian cancer. Gene expression analysis and mutation status indicated a high degree of similarity with the original patient and discriminate different subsets of xenografts. They were very responsive, responsive, and resistant to cisplatin, resembling the clinical situation in ovarian cancer. This panel of patient-derived EOC xenografts that recapitulate the recently type I and type II classi fication serves to study the biology of ovarian cancer, identify tumor-speci fi c molecular markers, and develop novel treatment modalities..
UR - http://www.scopus.com/inward/record.url?scp=84917706479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84917706479&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-14-0274
DO - 10.1158/0008-5472.CAN-14-0274
M3 - Article
C2 - 25304260
AN - SCOPUS:84917706479
VL - 74
SP - 6980
EP - 6990
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0008-5472
IS - 23
ER -